PIGN Biomarker Analysis for Hematologic Neoplasia Risk Prediction
Solution Overview
Problem
Current methods lack reliable markers for predicting the development or progression of hematological neoplasias such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), which are characterized by genomic instability and clonal evolution, necessitating effective prognostic indicators for early intervention.
Innovation Solution
The method involves determining biomarker levels, specifically mutated or wild-type phosphatidylinositol glycan anchor biosynthesis proteins and glycophosphatidylinositol-anchored proteins, to diagnose increased risk and progression of hematological neoplasias, using a comparative analysis with control levels, and providing tailored treatment recommendations, including modulators like PIGN activators or inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional classification methods are used for hematological neoplasias, then diagnostic procedures are established, but reliable prognostic markers for predicting development or progression are lacking
Solution Approach 1:
The patent segments the diagnostic approach by separating diagnostic classification from prognostic prediction. It identifies specific biomarkers (chromosomal abnormalities, gene mutations, protein expressions) that can be independently measured to predict disease progression risk, thus segmenting the prognostic information from the general diagnostic framework.
Solution Approach 2:
The patent applies preliminary action by identifying prognostic markers early in the disease course before progression occurs. By measuring biomarker levels (such as chromosomal instability markers or specific gene expressions) at diagnosis and during treatment, the method enables early prediction of transformation risk from MDS to AML, allowing preventive or early intervention strategies.
2Measurement precision
If genomic instability markers are measured to predict progression, then early detection capability is improved, but measurement and diagnostic complexity increases
Solution Approach 1:
The patent employs universal diagnostic approaches that can detect multiple prognostic markers through single or coordinated assays. For example, comprehensive chromosomal screening (karyotyping or FISH) simultaneously evaluates multiple chromosomal abnormalities, and gene expression profiling can assess multiple biomarkers in one test, reducing the need for separate complex procedures for each marker.
Solution Approach 2:
The patent utilizes parameter changes by measuring biomarker levels (such as chromosomal abnormality counts, gene expression levels, or protein concentrations) that quantitatively reflect genomic instability. These measurable parameters provide objective, precise indicators of progression risk that can be tracked over time, transforming complex genomic instability concepts into quantifiable diagnostic parameters.
Data Source
AI summary
The invention provides a method for determining the level of risk for development or progression of a hematologic neoplasia in a subject by analyzing the level of a phosphatidylinositol glycan anchor biosynthesis protein, and providing an appropriate treatment or preventive measure, on the basis of this risk.